---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-007980"
form_type: "8-K"
ticker: "AZTR"
cik: "0001701478"
company_name: "Azitra, Inc."
filed_at: "2025-02-24T23:59:59+00:00"
generated_at: "2026-05-26T06:00:17.943736+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Azitra reports FY2024 net loss of $9.0M; cash $4.6M; trial updates for ATR-12 and ATR-04

## Summary
- Net loss $9.0M vs $11.3M in FY2023; R&D expenses $4.7M, G&A $6.3M.
- Cash $4.6M at Dec 31, 2024; additional $2.2M raised in Jan/Feb 2025.
- Phase 1b trial of ATR-12 in Netherton syndrome ongoing; initial safety data expected H1 2025, topline by year-end.
- FDA cleared IND and granted Fast Track for ATR-04 for EGFRi rash; multicenter Phase 1/2 to start H1 2025.
- Closed $10M and $5M public offerings in 2024; IP portfolio strengthened.

## SEC filing metadata
- accession: 0001493152-25-007980
- form_type: 8-K
- ticker: AZTR
- cik: 0001701478
- company_name: Azitra, Inc.
- filed_at: 2025-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701478/000149315225007980/0001493152-25-007980-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701478/000149315225007980/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-007980
- JSON: https://secwatch.observer/filing/0001493152-25-007980.json
- Plain text: https://secwatch.observer/filing/0001493152-25-007980.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.